Keyword: Ultragenyx

In nine years, Ultragenyx grew from two employees to 700, striking partnerships, jumping into gene therapy through its acquisition of Dimension Therapeutics and getting two rare disease drugs to market.

Crysvita is the first FDA-approved drug for XLH, a rare, inherited form of rickets.